Borhane Annabi

Membres du laboratoire

• Alain Zgheib, Assistant de recherche
• Marie-Eve Roy, étudiante Ph.D.
• Carolane Veilleux, étudiante M.Sc.
• Sarah Kym Pépin, Étudiante M.Sc.
• Kaenon Prisca-Désiré Gnao, Étudiante M.Sc.
• Angélique Sabaoth Konan, étudiante M.Sc.
• Rosalie Zilinski, étudiante M.Sc.

Alumni

• Dr Mayya Meriane
• Dr Amel Guezguez
• Dr Reshu Gupta
• Dr Chirine Toufaily
• Dr David Beauchemin
• Dr Ana Carolina B. M. Martin
• Dr Khadidja Haidara
• Dr Sylvie Lamy
• Dr Michel Demeule
• Dr Cyndia Charfi
• Dr Amira Ouanouki
• Dr Khalil Abdelbaqi
• Dre Isabelle Cousineau
• Dre Maria de la Cruz Dominguez Punaro
• Dr Bogdan Alexandru Danalache
• Dr Naoufal Akla
• Dr Emmanuelle Boscher
• Jean-Christophe Currie
• Anissa Belkaid
• Simon Fortier
• Simon Lord-Dufour
• Martha Maria Cajina Herrera
• Carl Laflamme
• Asmaa Sina
• Elizabeth Tahanian
• Sébastien Proulx-Bonneau
• Éric Vaillancourt-Jean
• Naoufal Akla
• Rima Chokor
• Alain Zgheib
• Paula Liana Moldovan
• Michel Desjarlais
• Aroua Ben Saad
• Hana Benenemissi
• Pascale Gagné
• Samuel Burke-Nanni
• Samuel Sheehy
• Bayader Annabi
• Amélie Vézina
• Jonathan Pratt
• Laurence Lejeune
• Evelyne Muhire
• Clémence Bensiali-Haddaud
• Djahida Djerir
• Amira Ouanouki
• Wendenmi Tiziana Manuella Dao
• Marbelis Francisco Fernandez
• Audrey-Ann Sicard
• Samaneh Kamyabiazar
• Souad Djediai
• Véronique Lullier
• Virginie Desse
• Valérie Cabana
• Layal El Cheikh-Hussein
• Celia Kassouri
• Loraine Gresseau
• Sahily Rodriguez Torres
• Narjara Gonzalez Suarez
• Sima Torabidastgerdooei
• Meriem Benhamida

Chaire de Recherche en Prévention et Traitement du Cancer, directeur

Groupe d’étude des protéines membranaires (GÉPROM), membre associé

Réseau de Thérapie Cellulaire et Tissulaire ThéCELL, membre

Centre d’Excellence en Recherche sur les Maladies Orphelines, membre

Coalition Priorité Cancer au Québec, membre

Roy ME, Veilleux C, ANNABI B. (2024) In vitro biomaterial priming of human mesenchymal stromal/stem cells into 3D capillary-like structures : Implication of the Src/JAK/STAT3 signaling pathway in vasculogenic mimicry.  Scientific Reports  14(1):21444.

Akla N, Veilleux C, ANNABI B. (2024) The chemopreventive impact of diet-derived phytochemicals on the adipose tissue and breast tumor microenvironment secretome.  Nutrition and Cancer (doi: 10.1080/01635581.2024.2401647).

Roy ME, Veilleux C, Paquin A, Gagnon A, ANNABI B (2024) Transcriptional regulation of CYR61 and CTGF by LM98, a synthetic YAP/TEAD inhibitor that targets in vitro vasculogenic mimicry in glioblastoma cells.  Anti-Cancer Drugs  35(8):709-719

Demeule M, Currie JC, Charfi C, Zgheib A, Cousineau I, Lullier V, Béliveau R, Marsolais C, ANNABI B (2024) Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.  Frontiers in Immunology  15:1355945

Torabidastgerdooei S, Roy ME, and ANNABI B (2023) A molecular signature for the G6PC3 / SLC37A2 / SLC37A4 interactors in glioblastoma disease progression and in the acquisition of a brain cancer stem cell phenotype.  Frontiers in Endocrinology  14:1265698

Gonzalez Suarez N, Fernandez-Marrero Y, Hébert MPA, Roy ME, Boudreau LH, ANNABI B (2023) EGCG inhibits the inflammation and senescence inducing properties of MDA-MB-231 TNBC cells-derived extracellular vesicles in human adipose-derived mesenchymal stem cells.  Cancer Cell International  23(1):240

Rodriguez Torres S, Gresseau L, Benhamida M, Fernandez-Marrero Y, ANNABI B (2023) Epigallocatechin-3-gallate prevents the acquisition of a cancer stem cell phenotype in ovarian cancer tumorspheres through the inhibition of Src/JAK/STAT3 signaling.  Biomedicines  11(4):1000

Gomez Perez M, Gonzalez Suarez N, ANNABI B, Mateescu MA (2023) Bioactive copper (II) agents and their involvement in the treatment of copper deficiency-related orphan diseases.  Journal of Inorganic Biochemistry  247:112334

Gomez Perez M, Tanasie G, Neree AT, Gonzalez Suarez N, Lafortune C, Paquin J, Marcocci L, Pietrangeli P, ANNABI B, Mateescu MA (2023) P19-derived neuronal cells express H1, H2, and H3 histamine receptors: a biopharmaceutical approach to evaluate antihistamine agents.  Amino Acids  55(6):821-833

Fnaiche A, Chan HC, Paquin A, Gonzalez Suarez N, Vu V, Li F, Allali-Hassani A, Cao M, Szewczyk M, Bolotokova A, Allemand F, Gelin M, Barsyte-Lovejoy D, Santhakumar V, Vedadi M, Guichou JF, ANNABI B, Gagnon A (2023) Development of HC-258, a covalent acrylamide TEAD inhibitor that reduces gene expression and cell migration.  ACS Medicinal Chemistry Letters  14(12):1746-1753

Fnaiche A, Mélin L, González Suárez N, Vu V, Li F, Allali-Hassani A, Bolotokova A, Allemand F, Gelin M, Cotelle P, Woo S, LaPlante SR, Barsyte-Lovejoy D, Santhakumar V, Vedadi M, Guichou JF, ANNABI B, Gagnon A (2023) Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.  Bioorganic & Medicinal Chemistry Letters  95(2023):129488

Hajjar R, Gonzalez E, Oliero M, Alaoui AA, Fragoso G, Calvé A, Vennin Rendos H, Djediai S, Cuisiniere T, Laplante P, Gerkins C, Ajayi AS, Diop K, Taleb N, Thérien S, Shampaert F, Alratrout H, Dagbert F, Loungnarath R, Sebajang H, Schwenter F, Wassef R, Ratelle R, Debroux E, Routy B, Cailhier JF, ANNABI B, Brereton NJB, Richard C, Santos MM (2023) Gut microbiota influence anastomotic healing in colorectal cancer surgery through modulation of mucosal pro-inflammatory cytokines.  Gut  72(6):1143-1154

Gresseau L, Roy ME, Duhamel S, ANNABI B (2022) A signaling crosstalk links Snail to the 37/67 kDa laminin-1 receptor ribosomal protein SA and regulates the acquisition of a cancer stem cell molecular signature in U87 glioblastoma neurospheres.  Cancers  14(23):5944

Kassouri C, Rodriguez Torres S, Gonzalez Suarez N, Duhamel S, ANNABI B. EGCG Prevents the Transcriptional Reprogramming of an Inflammatory and Immune-Suppressive Molecular Signature in Macrophage-like Differentiated Human HL60 Promyelocytic Leukemia Cells. Cancers (Basel). 2022 Oct 16;14(20):5065

Demeule M, Charfi C, Currie JC, Zgheib A, Danalache BA, Béliveau R, Marsolais C, ANNABI B. The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells. Pharmaceutics. 2022 Sep 9;14(9):1910.

Currie JC, Demeule M, Charfi C, Zgheib A, Larocque A, Danalache BA, Ouanouki A, Béliveau R, Marsolais C, ANNABI B. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers (Basel). 2022 Apr 8;14(8):1877.

Gonzalez Suarez N, Fernandez-Marrero Y, Torabidastgerdooei S, ANNABI B. EGCG Prevents the Onset of an Inflammatory and Cancer-Associated Adipocyte-like Phenotype in Adipose-Derived Mesenchymal Stem/Stromal Cells in Response to the Triple-Negative Breast Cancer Secretome. Nutrients. 2022 Mar 5;14(5):1099.

Djediai S, Gonzalez Suarez N, El Cheikh-Hussein L, Rodriguez Torres S, Gresseau L, Dhayne S, Joly-Lopez Z, ANNABI B. MT1-MMP Cooperates with TGF-β Receptor-Mediated Signaling to Trigger SNAIL and Induce Epithelial-to-Mesenchymal-like Transition in U87 Glioblastoma Cells. Int J Mol Sci. 2021 Nov 30;22(23):13006.

Charfi C, Demeule M, Currie JC, Larocque A, Zgheib A, Danalache BA, Ouanouki A, Béliveau R, Marsolais C, ANNABI B (2021) New peptide-drug conjugates for precise targeting of SORT1-mediated vasculogenic mimicry in the tumor microenvironment of TNBC-derived MDA-MB-231 breast and ovarian ES-2 clear cell carcinoma cells.  Frontiers in Oncology  11:760787

Demeule M, Charfi C, Currie JC, Larocque A, Zgheib A, Kozelko S, Béliveau R, Marsolais C, ANNABI B (2021) TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.  Cancer Science  12(10):4317-4334

Uthamacumaran A, Gonzalez Suarez N, Baniré Diallo A, ANNABI B. (2021) Computational Methods for Structure-to-Function Analysis of Diet-Derived Catechins-Mediated Targeting of In Vitro Vasculogenic Mimicry.  Cancer Informatics  20:1-8

González Suárez N, Rodriguez Torres S, Ouanouki A, El Cheikh-Hussein L, ANNABI B (2021) EGCG inhibits adipose-derived mesenchymal stem cells differentiation into adipocytes and prevents a STAT3-mediated paracrine oncogenic control of triple-negative breast cancer cell invasive phenotype.  Molecules  26(6):1506

Sicard AA, Gonzalez Suarez N, Cappadocia L, ANNABI B (2021) Functional targeting of the TGF-βR1 kinase domain and downstream signaling: A role for the galloyl moiety of green tea-derived catechins in ES-2 ovarian clear cell carcinoma.  Journal of Nutritional Biochemistry  87:108518

Sicard AA, Dao T, Gonzalez Suarez N, ANNABI B (2021) Diet-derived gallated catechins prevent TGF-β-mediated epithelial-mesenchymal transition, cell migration and vasculogenic mimicry in chemosensitive ES-2 ovarian cancer cells.  Nutrition and Cancer  73(1):169-180

Abusarah J, Khodayarian F, El-Hachem N, Salame N, Olivier M, Balood M, Roversi K, Talbot S, Bikorimana JP, Chen J, Jolicoeur M, Trudeau LE, Kamyabiazar S, ANNABI B, Robert F, Pelletier J, El-Kadiry AE, Shammaa R, Rafei M. Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice. Cell Rep Med. 2021 Dec 21;2(12):100455.

Mélin L, Abdullayev S, Fnaiche A, Vu V, González Suárez N, Zeng H, Szewczyk MM, Li F, Senisterra G, Allali-Hassani A, Chau I, Dong A, Woo S, ANNABI B, Halabelian L, LaPlante SR, Vedadi M, Barsyte-Lovejoy D, Santhakumar V, Gagnon A. Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. ChemMedChem. 2021 Oct 6;16(19):2982-3002.

Hajjar R, Oliero M, Cuisiniere T, Fragoso G, Calvé A, Djediai S, ANNABI B, Richard CS, Santos MM. Improvement of colonic healing and surgical recovery with perioperative supplementation of inulin and galacto-oligosaccharides. Clin Nutr. 2021 Jun;40(6):3842-3851.

AbuSarah J., Cui Y., EL-Hachem N., El-Kadiry AE, Martel IH, Wurtele H, Beaudry A, Raynal N, Robert F, Pelletier J, Jankovic M, Mercier F, Kamyabiazar S, ANNABI B., Rafei M. (2021) TACIMA-218: A novel pro-oxidant agent exhibiting selective anti-tumoral activity.  Molecular Cancer Therapeutics  20(1):37-49